WARNING: RENAL FAILURE, HEPATIC FAILURE, AND GASTROINTESTINAL HEMORRHAGE - Renal Failure - JADENU can cause acute renal failure and death, particularly in patients with comorbidities and those who...+
Serum Ferritin Reduction
Make every milligram count when bringing down serum ferritin
Titrate to achieve effective iron reductions
- Demonstrated serum ferritin reductions with deferasirox were dose dependent1
- JADENU® (deferasirox) tablets was approved by the FDA based on equivalence to EXJADE® (deferasirox) tablets for oral suspension as demonstrated in pharmacokinetic studies of healthy subjects1
- 36% greater bioavailability of JADENU compared to EXJADE1
- JADENU was evaluated in healthy subjects. There are no clinical data in patients with JADENU1
MEAN SERUM FERRITIN REDUCTIONS1,2
Data presented here are based on clinical trial results with EXJADE 20- and 30-mg/kg/day doses.
JADENU may require dose adjustment, interruption, or cessation of therapy based on toxicity, serum ferritin, blood count, serum creatinine trends, severity of hepatic impairment, and/or concomitant UDP-glucuronosyltransferase (UGT) inducers/bile acid sequestrants.1
For additional dose adjustment information, please see Important Dose Limitations.
In a 1-year, open-label, multicenter, randomized, active comparator–controlled study, 586 patients aged ≥2 years with transfusion-dependent thalassemia were randomized to deferasirox oral suspension 5, 10, 20, or 30 mg/kg/day (equivalent to JADENU 3.5, 7, 14, and 21 mg/kg/day, respectively) (n=296) or subcutaneous deferoxamine 20 to 60 mg/kg/day (n=290) to assess success rates in reducing liver iron concentration (LIC) and to compare the changes in LIC and serum ferritin from baseline (21 mg/kg/day: 3768.5 μg/L; 14 mg/kg/day: 2276.9 μg/L) to the end of the study. Primary efficacy end point was success rate based on reduction in LIC.1,2
Liver Iron Concentration Reductions
Help reduce iron burden across anemias
Demonstrated LIC reductions with deferasirox were dose dependent1
- JADENU was approved by the FDA based on equivalence to EXJADE as demonstrated in pharmacokinetic studies of healthy subjects
- JADENU was evaluated in healthy subjects. There are no clinical data in patients taking JADENU. JADENU contains the same active ingredient as EXJADE
MEAN LIC REDUCTIONS AT 1 YEAR2-4
Data presented here are based on clinical trial results with EXJADE 20- and 30-mg/kg/day doses.
β-thalassemia: In a 1-year, open-label, multicenter, randomized, active comparator–controlled study, 586 patients aged ≥2 years with transfusion-dependent thalassemia were randomized to deferasirox oral suspension 5, 10, 20, or 30 mg/kg/day (equivalent to JADENU 3.5, 7, 14, and 21 mg/kg/day, respectively) (n=296) or subcutaneous deferoxamine 20 to 60 mg/kg/day (n=290) to assess success rates in reducing LIC and to compare the changes in LIC and serum ferritin from baseline (21 mg/kg/day: 3768.5 μg/L; 14 mg/kg/day: 2276.9 μg/L) to the end of the study. Primary efficacy end point was success rate based on reduction in LIC.1,2
SCD: In a 1-year, open-label, multicenter, randomized study, 195 transfusion-dependent patients with SCD were treated with deferasirox oral suspension (n=132) or subcutaneous deferoxamine (n=63) to compare the change in LIC from baseline to the end of the study. Primary efficacy end point was absolute change in LIC.1,3
MDS and chronic anemias: In a 1-year, open-label, noncomparative study, 184 transfusion-dependent patients with β-thalassemia (n=85), MDS (n=47), Diamond-Blackfan anemia (n=30), and other inherited or acquired chronic anemias (n=22) were enrolled to assess the change in LIC and serum ferritin from baseline to the end of the study. Primary efficacy end point was success rate based on reduction in LIC.1,4
dw, dry weight; MDS, myelodysplastic syndromes; SCD, sickle cell disease.
Reductions in Cardiac Iron
IMPROVE CARDIAC T2 VALUES
Cardiac T2* values improved in patients taking EXJADE with severe (<10 ms) and mild to moderate (≥10 ms to <20 ms) cardiac iron overload1
- The clinical significance of these findings is unknown1
- The geometric mean cardiac T2* increased from 11.98 ms at baseline to 17.12 ms after 3 years in 68 subjects who completed 3 years of EXJADE therapy1
In a 3-year study, 105 thalassemia patients with cardiac iron overload were evaluated to assess the change in cardiac magnetic resonance imaging T2* value (in milliseconds) before and after treatment with deferasirox oral suspension.1
1. Jadenu [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2019. 2. Data on file. Study CICL670A0107. Novartis Pharmaceuticals Corp; 2005. 3. Data on file. Study. CICL670A0109. Novartis Pharmaceuticals Corp; 2005. 4. Data on file. Study CICL 670A0108. Novartis Pharmaceuticals Corp; 2005.
TELESTO Study Brochure
Download this brochure to see clinical trial data that may affect how you treat iron overload in patients with low- and intermediate-risk myelodysplastic syndromes.
Treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload)
JADENU® (deferasirox) tablets for oral use and JADENU® Sprinkle (deferasirox) granules are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Limitation of Use
The safety and efficacy of JADENU, when administered with other iron chelation therapy, have not been established.
IMPORTANT SAFETY INFORMATION for JADENU® (deferasirox) tablets for oral use and JADENU® Sprinkle (deferasirox) granules
JADENU is contraindicated in patients with:
- Estimated GFR ˂40 mL/min/1.73 m2;
- Poor performance status;
- High-risk myelodysplastic syndromes (MDS);
- Advanced malignancies;
- Platelet counts <50 x 109/L;
- Known hypersensitivity to deferasirox or any component of JADENU
WARNINGS AND PRECAUTIONS
Acute Kidney Injury, Including Acute Renal Failure Requiring Dialysis and Renal Tubular Toxicity Including Fanconi Syndrome
JADENU is contraindicated in patients with eGFR ˂40 mL/min/1.73m2. Exercise caution in pediatric patients with eGFR between 40 and 60 mL/min/1.73 m2. If treatment is needed, use the minimum effective dose and monitor renal function frequently. Individualize dose titration based on improvement in renal injury. For patients with renal impairment (eGFR 40 to 60 mL/min/1.73m2), reduce the starting dose by 50%.
JADENU can cause acute kidney injury including renal failure requiring dialysis that has resulted in fatal outcomes. Based on postmarketing experience, most fatalities have occurred in patients with multiple comorbidities and who were in advanced stages of their hematologic disorders. In the clinical trials, adults and pediatric patients treated with deferasirox with no preexisting renal disease experienced dose-dependent mild, nonprogressive increases in serum creatinine and proteinuria. Preexisting renal disease and concomitant use of other nephrotoxic drugs may increase the risk of acute kidney injury in adult and pediatric patients. Acute illnesses associated with volume depletion and overchelation may increase the risk of acute kidney injury in pediatric patients. In pediatric patients, small decreases in eGFR can result in increases in deferasirox exposure, particularly in younger patients with body surface area typical of patients ˂7 years of age. This can lead to a cycle of worsening renal function and further increases in deferasirox exposure, unless the dose is reduced or interrupted. Renal tubular toxicity, including acquired Fanconi Syndrome, has been reported in patients treated with deferasirox, most commonly in pediatric patients with β-thalassemia and serum ferritin levels ˂1500 mcg/L. Evaluate renal glomerular and tubular function before initiating therapy or increasing the dose. Use prediction equations validated for use in adult and pediatric patients to estimate GFR. Obtain serum electrolytes and urinalysis in all patients to evaluate renal tubular function.
Monitor all patients for changes in eGFR and for renal tubular toxicity weekly during the first month after initiation or modification of therapy, and at least monthly thereafter. Monitor serum ferritin monthly to evaluate for overchelation. Use the minimum dose to establish and maintain a low iron burden. Monitor renal function more frequently in patients with preexisting renal disease or decreased renal function. In pediatric patients, interrupt JADENU during acute illnesses that can cause volume depletion such as vomiting, diarrhea, or prolonged decreased oral intake, and monitor renal function more frequently. Promptly correct fluid deficits to prevent renal injury. Resume therapy as appropriate, based on assessments of renal function, when oral intake and volume status are normal.
Hepatic Toxicity and Failure
JADENU can cause hepatic injury, fatal in some patients. In Study 1, 4 (1.3%) patients discontinued deferasirox because of hepatic toxicity (drug-induced hepatitis in 2 patients and increased serum transaminases in 2 additional patients). Hepatic toxicity appears to be more common in patients >55 years of age. Hepatic failure was more common in patients with significant comorbidities, including liver cirrhosis and multiorgan failure.
Acute liver injury and failure, including fatal outcomes, have occurred in pediatric patients treated with deferasirox. Liver failure occurred in association with acute kidney injury in pediatric patients at risk for overchelation during a volume-depleting event. Interrupt JADENU therapy when acute liver injury, or acute kidney injury, is suspected and during volume depletion. Monitor liver and renal function more frequently in pediatric patients who are receiving JADENU in the 14 to 28 mg/kg/day range, and when iron burden is approaching normal. Use the minimum effective dose to achieve and maintain a low iron burden.
Measure aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and bilirubin in all patients before the initiation of treatment and every 2 weeks during the first month, and at least monthly thereafter. Consider dose modifications or interruption of treatment for severe or persistent elevations.
Avoid the use of JADENU in patients with severe (Child-Pugh C) hepatic impairment. Reduce the starting dose in patients with moderate (Child-Pugh B) hepatic impairment. Patients with mild (Child-Pugh A), or moderate (Child-Pugh B) hepatic impairment, may be at higher risk for hepatic toxicity.
Gastrointestinal Ulceration, Hemorrhage, and Perforation
Gastrointestinal (GI) hemorrhage, including deaths, has been reported, especially in elderly patients who had advanced hematologic malignancies and/or low platelet counts. Nonfatal upper GI irritation, ulceration, and hemorrhage have been reported in patients, including children and adolescents, receiving deferasirox. Monitor for signs and symptoms of GI ulceration and hemorrhage during JADENU therapy, and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. The risk of GI hemorrhage may be increased when administering JADENU in combination with drugs that have ulcerogenic or hemorrhagic potential such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. There have been reports of ulcers complicated with GI perforation (including fatal outcome).
Bone Marrow Suppression
Neutropenia, agranulocytosis, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox. Preexisting hematologic disorders may increase this risk. Monitor blood counts in all patients. Interrupt treatment with JADENU in patients who develop cytopenias until the cause of the cytopenia has been determined. JADENU is contraindicated in patients with platelet counts ˂50 x 109/L.
Age-Related Risk of Toxicity
Elderly Patients: JADENU has been associated with serious and fatal adverse reactions in the postmarketing setting among adults, predominantly in elderly patients. Monitor elderly patients treated with JADENU more frequently for toxicity.
Pediatric Patients: JADENU has been associated with serious and fatal adverse reactions in pediatric patients in the postmarketing setting. These events were frequently associated with volume depletion or with continued EXJADE® (deferasirox) tablets for oral suspension doses in the 20 to 40 mg/kg/day range, equivalent to 14-28 mg/kg/day JADENU, when body iron burden was approaching or was in the normal range. Interrupt JADENU in patients with volume depletion, and resume JADENU when renal function and fluid volume have normalized. Monitor liver and renal function more frequently during volume depletion, and in patients receiving JADENU in the 14 to 28 mg/kg/day range, when iron burden is approaching the normal range. Use the minimum effective dose to achieve and maintain a low iron burden.
For patients with transfusional iron overload, measure serum ferritin monthly to assess for possible overchelation of iron. An analysis of pediatric patients treated with EXJADE in pooled clinical trials (n=158) found a higher rate of renal adverse events among patients receiving doses >25 mg/kg/day, equivalent to 17.5 mg/kg/day JADENU, while their serum ferritin values were ˂1000 mcg/L. Consider dose reduction or closer monitoring of renal and hepatic function, and serum ferritin levels during these periods. Use the minimum effective dose to maintain a low iron burden.
If the serum ferritin is ˂1000 mcg/L at 2 consecutive visits, consider dose reduction, especially if the JADENU dose is >17.5 mg/kg/day [see Adverse Reactions (6.1)]. If the serum ferritin is ˂500 mcg/L, interrupt therapy with JADENU and continue monthly monitoring. Evaluate the need for ongoing chelation for patients whose conditions do not require regular blood transfusions. Use the minimum effective dose to maintain iron burden in the target range. Continued administration of JADENU in the 14 to 28 mg/kg/day range, when the body iron burden is approaching or is within the normal range, can result in life-threatening adverse events.
JADENU may cause serious hypersensitivity reactions (such as anaphylaxis and angioedema), with the onset of the reaction usually occurring within the first month of treatment. If reactions are severe, discontinue JADENU and institute appropriate medical intervention. JADENU is contraindicated in patients with known hypersensitivity to deferasirox products and should not be reintroduced in patients who have experienced previous hypersensitivity reactions on deferasirox products due to the risk of anaphylactic shock.
Severe Skin Reactions
Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) which could be life-threatening or fatal, have been reported during deferasirox therapy. Cases of erythema multiforme have been observed. Advise patients of the signs and symptoms of severe skin reactions, and closely monitor. If any severe skin reactions are suspected, discontinue JADENU immediately and do not reintroduce JADENU therapy.
Rashes may occur during JADENU treatment. For rashes of mild to moderate severity, JADENU may be continued without dose adjustment since the rash often resolves spontaneously. In severe cases, interrupt treatment with JADENU. Reintroduction at a lower dose, with escalation, may be considered after resolution of the rash.
Auditory and Ocular Abnormalities
Auditory disturbances (high-frequency hearing loss, decreased hearing), and ocular disturbances (lens opacities, cataracts, elevations in intraocular pressure, and retinal disorders) were reported at a frequency of <1% with deferasirox therapy in the clinical studies. The frequency of auditory adverse events, irrespective of causality, was increased among pediatric patients who received EXJADE doses >25 mg/kg/day, equivalent to 17.5 mg/kg/day JADENU, when serum ferritin was ˂1000 mcg/L.
Perform auditory and ophthalmic testing (including slit-lamp examinations and dilated fundoscopy) before starting JADENU treatment and thereafter at regular intervals (every 12 months). If disturbances are noted, monitor more frequently. Consider dose reduction or interruption.
JADENU was evaluated in healthy subjects, and there are no clinical data in patients treated with JADENU tablets or JADENU Sprinkle granules. JADENU contains the same active ingredient, deferasirox, as EXJADE® (deferasirox) tablets for oral suspension. For patients with transfusional iron overload, the most common adverse reactions occurring in >5% of patients treated with deferasirox who have β-thalassemia, sickle cell disease, and MDS were abdominal pain, nausea, vomiting, diarrhea, skin rashes, and increases in serum creatinine. Gastrointestinal symptoms, increases in serum creatinine, and skin rash were dose related.
Please see full Prescribing Information, including Boxed WARNING, for JADENU® (deferasirox) tablets for oral use and JADENU® Sprinkle (deferasirox) granules.